AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
EMERYVILLE, Calif., April 26, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until June 3, 2018.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
